Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$0.00
$0.00
$0.00
$0.03
$6K1.277,876 shs666 shs
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
$0.00
$0.02
$9K0.7913,056 shs1 shs
MusclePharm Co. stock logo
MSLP
MusclePharm
$0.00
$0.00
$0.00
$7K-0.0726,442 shsN/A
Sienna Biopharmaceuticals, Inc. stock logo
SNNAQ
Sienna Biopharmaceuticals
$0.00
$0.00
$0.00
N/A0.31N/AN/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00%0.00%0.00%0.00%-99.25%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%0.00%0.00%0.00%+150.00%
MusclePharm Co. stock logo
MSLP
MusclePharm
0.00%0.00%0.00%0.00%-83.33%
Sienna Biopharmaceuticals, Inc. stock logo
SNNAQ
Sienna Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/AN/AN/AN/A
Sienna Biopharmaceuticals, Inc. stock logo
SNNAQ
Sienna Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
0.00
N/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00
N/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
0.00
N/AN/AN/A
Sienna Biopharmaceuticals, Inc. stock logo
SNNAQ
Sienna Biopharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
$1.00M0.01N/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
$50.04M0.00N/AN/A($0.94) per share0.00
Sienna Biopharmaceuticals, Inc. stock logo
SNNAQ
Sienna Biopharmaceuticals
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
-$18MN/A0.00N/AN/AN/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$114.53MN/A0.00N/AN/AN/AN/A7/7/2025 (Estimated)
MusclePharm Co. stock logo
MSLP
MusclePharm
-$12.87M-$0.58N/AN/AN/A-38.51%N/A-169.56%N/A
Sienna Biopharmaceuticals, Inc. stock logo
SNNAQ
Sienna Biopharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/AN/AN/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/AN/AN/AN/AN/A
Sienna Biopharmaceuticals, Inc. stock logo
SNNAQ
Sienna Biopharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/A
MusclePharm Co. stock logo
MSLP
MusclePharm
N/A
0.25
0.23
Sienna Biopharmaceuticals, Inc. stock logo
SNNAQ
Sienna Biopharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
N/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.31%
MusclePharm Co. stock logo
MSLP
MusclePharm
15.49%
Sienna Biopharmaceuticals, Inc. stock logo
SNNAQ
Sienna Biopharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
8.90%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
1.02%
MusclePharm Co. stock logo
MSLP
MusclePharm
60.70%
Sienna Biopharmaceuticals, Inc. stock logo
SNNAQ
Sienna Biopharmaceuticals
27.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Comera Life Sciences Holdings, Inc. stock logo
CMRA
Comera Life Sciences
230.74 million28.00 millionNot Optionable
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
12018.98 million18.79 millionNo Data
MusclePharm Co. stock logo
MSLP
MusclePharm
2033.39 million13.12 millionNot Optionable
Sienna Biopharmaceuticals, Inc. stock logo
SNNAQ
Sienna Biopharmaceuticals
60N/AN/ANot Optionable

Recent News About These Companies

SNNAQ Sienna Biopharmaceuticals, Inc.
Sienna Announces Change of timing to Third Quarter 2024 Conference Call
What is Sienna Miller's Net Worth?
Hollyoaks spoiler: Sienna and Ethan face opposition
2025 Toyota Sienna Adds New Interior Tech and Bumps Price
Princess Beatrice daughter Sienna’s noble title revealed
The Refreshed 2025 Toyota Sienna Literally Sucks

Media Sentiment Over Time

Comera Life Sciences stock logo

Comera Life Sciences NASDAQ:CMRA

$0.0002 0.00 (0.00%)
As of 09:35 AM Eastern

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Evelo Biosciences stock logo

Evelo Biosciences NASDAQ:EVLO

$0.0005 0.00 (0.00%)
As of 07/3/2025

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

MusclePharm stock logo

MusclePharm OTCMKTS:MSLP

MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.

Sienna Biopharmaceuticals stock logo

Sienna Biopharmaceuticals OTCMKTS:SNNAQ

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.